Due to a national shortage of blood collection tubes, you may experience upwards of a 2-hour delay in processing time for certain tests. Someone from our team will advise you if your scheduled lab test is affected by this delay. We thank you in advance for your patience.

Clinical Trials & Research

View Open Trials

Anal

  • Ph3 Carbo/Pac NCMGA00012 MSCC

    A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)


Bladder

  • 21216 - Ph2 Trila Avel Uro Carcinoma

    A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)(G1T28-209)


  • PH 2 Enfortumab in Urothelial Pts

    A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)


  • Pembro in combo CRT vs CRT alnoe MIBC

    Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)


  • Ph3 FGFR erdafitinib urothelial

    (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)


  • Sitravatinib + Nivo Adv/Met Urothelial

    A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)


  • NeoAdj Chemo +/- Nivo/IDO1inh MIBC

    A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)


Breast

  • Ph3 Abem HR+ HER2+ BC

    eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy (I3Y-MC-JPCW)


  • Registry study with Breast Cancer Index

    Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)


  • Ph1/2 Ibrutinib+Tras HER2 amp/MBC

    Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer


  • Ph 3 Tuca/Placbo + T-DM1 HER2+

    STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)


  • FLEX Registry: Evaluate New Gene Express

    MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)


Leukemia

  • PH3 Ven+G vs FCR/BR in Fit untreated CLL

    A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)


Lung (Non Small Cell)

  • Ph2 MRTX849 Pembro NSCLC KRAS

    A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)


  • Ph3 Adj Selp St1B/3 RET+ NSCLC

    A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)


  • Ph1/2 MRTX849 Solids KRAS G12C

    A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)


  • KEAP1/NRF2 NSCLC

    CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)


  • PH3 pral(Blu-667) RET-fusion mNSCLC

    A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)


  • PH3 Osi +/- Platinum Chemo/Pem NSCLC

    A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2) (D5169C00001)


  • PH3 Atez Tira Dura Sg 3 NSCLC

    GO41854: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)


  • Ph2 IMMU-132 met Solid Tumors

    A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)


  • BIODESIX

    Clinical Effectiveness Assessment of VeriStrat© Testing and Validation of Immunotherapy Tests in NSCLC Subjects (INSIGHT)


Lymphomas

  • Ph2 Oral Taze +Ritu r/r FL

    EZH-1401 - A PHASE II OPEN-LABEL, MULTICENTER TRIAL OF ORAL TAZEMETOSTAT IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA


  • Ph2 A+AVD +G-CSF or AOAD in CHL

    SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects


  • PH3 R-CHOP +/- Acalab Tx Naive DLBCL

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (ACE-LY-312/ D8227C00001)


  • Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

    A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)


  • BV in older pts w/1L cHL or PTCL

    (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy


Melanoma

  • Ph2 Selinexor + Pembro Newly Dx Melanoma

    A PHASE 2 OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SELINEXOR IN COMBINATION WITH PEMBROLIZUMAB IN RECURRENT ADVANCED MELANOMA (XPORT-MEL-033)


Prostate

  • PH3 Nirap Abira HRR mCSPC

    A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)


  • Ph3 Nivo +/- Doce mPC 7DX

    A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CA209-7DX)


  • Biomarker DNA Defect Men Prostate

    Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)


Renal

  • MK-6482 Advanced Renal Cell Carcinoma

    MK6482-013: Phase 2 Study of MK-6482 in Participants with Advanced Renal Cell Carcinoma


  • PH3 Ate +Cabo Renal Carcinoma

    A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT (WO41994)


  • GU-102 Ph I/II Nivo + axitinib RCC

    Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma


Solid Tumors

  • 20297 - Ph1/2 BDC-1001 +/- Pembro HER2 Solids

    Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced HER2-Expressing Solid Tumors (BBI-20201001)


  • Ph1/2 BDC-1001 +/- Pembro HER2 Solids

    Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced HER2-Expressing Solid Tumors (BBI-20201001)


  • Ph2 Basket Tucat+Tras ST HER2 Alt

    A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)


  • Ph2 Bren Vedo + Pembro ST prior PD-1

    A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)


  • Ph2 Erdafitinib FGFR Solid Tumors

    A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)


  • Ph 1 CPI-006+444/Pembro ST/NHL

    A PHASE 1/1B MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS (CPI-006-001)


  • Ph1/2 BLU667 thy, NSCLC, Sol tum

    A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)


Multiple Myeloma

  • 20285 - Ph2 Dara Lena Dexa (DRd) MM I

    A phase II trial of daratumumab, lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)


  • PH3 Dara/Len vs Len NDMM

    A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)


Myelofibrosis

  • Ph3 Navi Ruxo Myelofibrosis

    M16-191: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)


  • PH3 Pacritinib vs MD choice in MF

    A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)